Advertisement

Organisation › Details
Bicycle Therapeutics (Group)
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. *
![]() |
Start | 2009-10-06 splitoff |
Today | Bicycle Therapeutics Ltd. | |
Predecessor | MRC (GB), Laboratory of Molecular Biology (MRC-LMB, Cambridge) | |
![]() |
Industry | Bicycle Drug Conjugates® |
Industry 2 | phage display technology | |
![]() |
Person | Lee, Kevin (Bicycle Therapeutics 201509– CEO before Pfizer + GSK) |
Person 2 | Winter, Gregory (MRC + CAT + Domantis + Nobel Laureate) | |
![]() |
Region | Cambridge, Cambridgeshire |
Country | United Kingdom (GB) | |
Street | Blocks A & B Portway Building Granta Park, Great Abington | |
City | CB21 6GP Cambridge, Cambridgeshire | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2023-12-31) |
Currency | USD | |
Annual sales | 25,859,000 (revenue, consolidated (2023) 2023-12-31) | |
Profit | -168,578,000 (2023-12-31) | |
Cash | 526,423,000 (2023-12-31) | |
* Document for »About Section«: Bicycle Therapeutics plc. (6/23/23). "Press Release: Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer". Cambridge & Boston, MA. | ||
Record changed: 2024-05-23 |
Advertisement

More documents for Bicycle Therapeutics (Group)
- [1] Bicycle Therapeutics plc. (6/3/24). "Press Release: Bicycle Therapeutics to Participate in Upcoming Investor Conferences". Cambridge & Boston, MA....
- [2] Bicycle Therapeutics plc. (10/30/23). "Press Release: Bicycle Therapeutics to Participate in Upcoming Investor Conferences". Cambridge....
- [3] Bicycle Therapeutics plc. (7/18/23). "Press Release: Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares". Cambrid...
- [4] Bicycle Therapeutics plc. (7/12/23). "Press Release: Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares". Cambridge & Boston, MA....
- [5] Bicycle Therapeutics plc. (7/12/23). "Press Release: Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares". Cambridge & Boston, MA....
- [6] Bicycle Therapeutics plc. (6/23/23). "Press Release: Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer". Cambridge & Boston, MA....
- [7] Bicycle Therapeutics plc. (5/10/23). "Press Release: Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology". Berlin, Cambridge & Boston, MA....
- [8] Bicycle Therapeutics plc. (5/4/23). "Press Release: Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets". Cambridge & Boston,...
- [9] Bicycle Therapeutics plc. (3/28/23). "Press Release: Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates". Cambridge & Boston, MA....
- [10] Owlstone Medical Ltd.. (3/15/23). "Press Release: Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top